Hongzhi Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hongzhi Xu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Aili Zhang
School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China
1 shared publication - Bo Cao
School of Biomedical Engineering, Shanghai Jiao Tong University, No. 1954, Huashan Road, Xuhui District, Shanghai, China, Shanghai, 200030, China
1 shared publication Hongying Wang
School of Biomedical Engineering, Shanghai Jiao Tong University, No. 1954, Huashan Road, Xuhui District, Shanghai, China, Shanghai, Shanghai, 200030, China
1 shared publicationLinyang Wei
School of Biomedical Engineering, Shanghai Jiao Tong University, No. 1954, Huashan Road, Xuhui District, Shanghai, China, Shanghai, Shanghai, 200030, China
1 shared publicationMing Xu
Department of Anaesthesiology, Huashan Hospital Fudan University, No. 12, Middle Wulumuqi Road, Jing'an District, Shanghai, China, Shanghai, Shanghai, 200040, China
1 shared publication- Shiqing Zhao
School of Biomedical Engineering, 400 Med-X Research Institute, Shanghai Jiao Tong University, 1954 Huashan Road, Shanghai 200030, China
1 shared publication
Latest Publications
- 9 April 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (8)
Electrothermal decoupling for investigating tumor treating fields of glioblastoma
Objective: Tumor Treating Fields (TTFields), a non-invasive cancer therapy employing low-intensity alternating electric fields to inhibit cancer cell division, has been used to treat glioblastoma. While clinically established for glioblastoma, the biological contribution of the intrinsic mild hyperthermia (iMH) remains not fully elucidated, limiting mechanistic clarity and treatment optimization. Approach: This study presents a precision in vitro platform designed to decouple the electrical and thermal components of TTFields (230 kHz, 2 V/cm). Based on numerical simulations, the platform utilizes a defined monitoring area to ensure field uniformity and an active thermodynamic compensation protocol to isolate electric and thermal modalities. Main results: Results indicated that the electric field primarily inhibited cell proliferation (32.0% reduction) and migration, whereas the iMH was the primary mediator of cytotoxicity and apoptosis. Notably, the combined electrothermal treatment exhibited a synergistic anti-tumor effect exceeding the additive effects of individual modalities. Significance: These findings suggest that the iMH component of TTFields functions as a therapeutic sensitizer rather than a side effect, offering a basis for optimizing future GBM treatment strategies.
- 9 April 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (8)
Electrothermal decoupling for investigating tumor treating fields of glioblastoma
Objective: Tumor Treating Fields (TTFields), a non-invasive cancer therapy employing low-intensity alternating electric fields to inhibit cancer cell division, has been used to treat glioblastoma. While clinically established for glioblastoma, the biological contribution of the intrinsic mild hyperthermia (iMH) remains not fully elucidated, limiting mechanistic clarity and treatment optimization. Approach: This study presents a precision in vitro platform designed to decouple the electrical and thermal components of TTFields (230 kHz, 2 V/cm). Based on numerical simulations, the platform utilizes a defined monitoring area to ensure field uniformity and an active thermodynamic compensation protocol to isolate electric and thermal modalities. Main results: Results indicated that the electric field primarily inhibited cell proliferation (32.0% reduction) and migration, whereas the iMH was the primary mediator of cytotoxicity and apoptosis. Notably, the combined electrothermal treatment exhibited a synergistic anti-tumor effect exceeding the additive effects of individual modalities. Significance: These findings suggest that the iMH component of TTFields functions as a therapeutic sensitizer rather than a side effect, offering a basis for optimizing future GBM treatment strategies.